noscript

News and Announcements

Dimerix’s Latest Research Validating the Relevance of DMX Receptor-HIT Technology Published in Scientific Reports Journal

  • Published June 13, 2017 12:00AM UTC
  • Publisher Wholesale Investor
  • Categories Company Updates

Dimerix Limited (ASX: DXB), a clinical-stage biotechnology company discovering and developing new therapeutic treatments identified using its proprietary assay technology today announce the publication of important research by Chief Scientific Advisor, Associate Professor Kevin Pfleger and colleagues in the leading peer reviewed journal Scientific Reports.

KEY TAKEAWAYS:

  • Using state-of-the-art CRISPR technology, the team at the Harry Perkins Institute of Medical Research led by Associate Professor Pfleger has developed world first tools for studying functional receptor interactions in real time.
  • Validate the relevance of the Dimerix Receptor-Heteromer Investigation Technology platform to monitor receptor complexes by labelling and monitoring endogenous receptors with tags for bioluminescence resonance energy transfer.
  • The Receptor-HIT technology was used to identify DMX-200, Dimerix’s lead clinical stage drug development program, in Phase II of trials for the treatment of chronic kidney disease.

Associate Professor Pfleger highlighted that “This work has considerable potential for improving drug discovery and profiling, leveraging both Dimerix’s Receptor-HIT platform and the latest advances in genome editing”.

Dimerix’S CEO Kathy Harrison said: “Validation of the power of platform technologies which rely on analysis in vitro can be challenging. This pivotal piece of work has shown that the relevance of the heterodimers (the core premise of Receptor-HIT technology) can be demonstrated in cells in real time under endogenous promoter conditions, as occurs in the physiological setting.”

More Information 

Request Information 

Capital Insights
The Index Approach in Early-Stage Venture Capital: Reconsidered

The venture capital (VC) landscape is marked by its dynamism and complexity, especially in early-stage investing. The traditional approach in VC, characterised by a selective and intensive vetting process, often contrasts with the concept of ‘index investing.’ This article revisits the indexing approach in early-stage VC, incorporating insights from recent studies and data, including a […]

Capital Insights
The Future Is Now: The Evolution of Dealflow with Wholesale Investor

If you’ve ever thought of investing or expanding your portfolio, there’s no better time than the present. In the fast-paced world of investment, things are changing at a breathtaking speed, and it’s crucial to stay ahead of the game. The Future of Deal Flow is Today Dealflow, the lifeblood of the investment world, is not […]

Join over 45,000+ sophisticated investors

Join Now